Syncom Formulations (India) Ltd. (SYNCOMF) Share Price Rises 10.73% Today

Syncom Formulations (India) Ltd. Share Price rose to Rs 16.1 on 12 August 2026, up 10.73% for the day, lifting the company’s market capitalisation to Rs 1,353.6 crore. The stock’s move placed it in focus as a small-cap pharmaceutical name recording a notable same-day price rise, with verified trading data showing a clear jump over the previous close of Rs 14.54.

For investors tracking Syncom Formulations (India) Ltd. Share Price Today, the move matters because it combined a strong percentage gain with active participation across exchanges. The stock opened at Rs 15.5, touched an intraday high of Rs 17.16 and a low of Rs 15.25, while total traded volume stood at 4,30,08,703 shares. On BSE alone, volume was 24,58,312 shares, while NSE volume reached 4,05,50,391 shares. Turnover on the captured exchange data stood at Rs 3.96 crore.

What the supplied data confirms is the price event itself: Syncom Formulations (India) Ltd. Share Price is rising today, the stock is trending among market movers, and the gain is large enough for the company to qualify under a price-rise screen for its small-cap category. What the data does not independently establish is any company-specific catalyst behind today’s move. That makes the discussion especially relevant for investors who want to separate price action from business quality, valuation, industry context and peer positioning. In this Univest stock analysis, the focus stays on verified numbers: price, market capitalisation, valuation ratios, profitability, sector benchmarks and peer comparison.

Syncom Formulations (India) Ltd. (SYNCOMF) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 16.1
Previous Close	Rs 14.54
Today's Change	+Rs 1.56 (+10.73%)
Day Open	Rs 15.5
Day High	Rs 17.16
Day Low	Rs 15.25
Current Volume (BSE)	24,58,312
BSE Traded Volume	24,58,312
NSE Traded Volume	4,05,50,391
Combined NSE + BSE Volume	4,30,08,703
Turnover	Rs 3.96 crore
Market Capitalisation	Rs 1,353.6 crore
Market Cap Category	Small Cap

Syncom Formulations (India) Ltd. (SYNCOMF) traded at Rs 16.1. versus the previous close of Rs 14.54, a rise of 10.73%. The stock opened at Rs 15.5, reached Rs 17.16, touched Rs 15.25. Reported volume was 24,58,312.

Syncom Formulations (India) Ltd. (SYNCOMF) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,353.6 crore
P/E Ratio	17.88x
P/B Ratio	3.29x
ROE	18.04%
ROCE	20.72%
EPS	Rs 0.81
Dividend Yield	0%

Syncom Formulations (India) Ltd. was valued at a P/E ratio of 17.88x, a P/B ratio of 3.29x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 18.04% and ROCE of 20.72%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 0.81, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Syncom Formulations (India) Ltd. Fundamental Analysis suggests that the stock’s market attention is not based on size alone. The company’s market capitalisation is Rs 1,353.6 crore, and its supplied valuation and profitability metrics place it in a part of the pharmaceuticals universe where investors can compare operating returns with market pricing rather than relying only on momentum.

The stock is trading at a price-to-earnings ratio of 17.88 and a price-to-book ratio of 3.29. In isolation, those are simply valuation multiples, but they become more useful when seen alongside profitability. Return on equity stands at 18.04%, while return on capital employed is 20.72%. Those levels indicate that the company is generating returns above the double-digit range on both shareholder equity and capital employed, which is often an important filter in healthcare and pharmaceuticals stock analysis.

EPS is Rs 0.81. That figure represents the earnings attributable to each share and gives context to how the market is valuing current profitability through the P/E ratio of 17.88. The company’s dividend yield is 0, which means the current data set reflects no cash yield from dividend relative to the present share price. For investors focused on reinvestment-oriented small caps, that shifts attention more toward earnings efficiency and valuation than toward income distribution.

The combination of a 17.88 P/E, 3.29 P/B, 18.04% ROE and 20.72% ROCE gives Syncom Formulations (India) Ltd. Share Price a clearer fundamental backdrop than a price move alone would suggest. It does not prove that today’s rally came from any specific corporate event, but it does show that the company is not being viewed through a pure loss-making or extremely stretched-profitability lens in the supplied data. From a Univest perspective, this is the kind of setup where market participants usually watch whether price action is being supported by business quality and sector-relative valuation.

That naturally leads to the bigger question: how do these numbers compare with the wider pharmaceuticals and drugs benchmark the company operates within?

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	17.88x
Benchmark Median P/E	24.45x
Benchmark Average P/E	79.31x
Benchmark P/E Range	3.31x to 3,374.81x
Company P/B Ratio	3.29x
Benchmark Median P/B	1.82x
Company ROE	18.04%
Benchmark Median ROE	10.49%
Company ROCE	20.72%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 1,353.6 crore
Benchmark Median Market Cap	Rs 146.94 crore

Syncom Formulations (India) Ltd. (SYNCOMF) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 17.88x, which is below the benchmark median of 24.45x, a difference of -26.87%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Syncom Formulations (India) Ltd. (SYNCOMF) has a ROE of 18.04%, which is above the benchmark median of 10.49%, a difference of +71.97%. Syncom Formulations (India) Ltd. (SYNCOMF) has a ROCE of 20.72%, which is above the benchmark median of 12.97%, a difference of +59.75%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Syncom Formulations (India) Ltd. operates in Healthcare under the Pharmaceuticals & Drugs industry, and the supplied same-industry benchmark gives useful context. The company’s valuation sits below the benchmark median on P/E, while its profitability ratios stand above median industry levels, making the stock notable from a sector-comparison angle.

The benchmark scope is explicitly the same industry, covering 136 companies in Pharmaceuticals & Drugs. Within that universe, the company’s P/E ratio is 17.88. That compares with a benchmark median P/E of 24.45 and an average P/E of 79.31, based on 104 companies with available P/E data. The wider range runs from 3.31 to 3,374.81, which shows how dispersed valuations are across the industry. Against that backdrop, Syncom Formulations (India) Ltd. Share Price is not trading at the benchmark median multiple; its P/E is lower than both the median and the average.

The picture is different on price-to-book. The company’s P/B ratio is 3.29, versus a benchmark median of 1.82 and an average of 2.46 across 135 companies. The industry P/B range runs from -16.74 to 16.32. So while earnings-based valuation appears below the industry median, book-based valuation is above both median and average levels in the supplied sample.

Profitability stands out more positively. The company’s ROE of 18.04% is above the benchmark median of 10.49% and the average of 8.1%. Its ROCE of 20.72% is also above the benchmark median of 12.97% and the average of 15.64%. Market-cap context is equally relevant: at Rs 1,353.6 crore, the company is larger than the industry median market capitalisation of Rs 146.94 crore and the average of Rs 484.32 crore, within a range of Rs 6.31 crore to Rs 2,949.87 crore.

For readers following Syncom Formulations (India) Ltd. Stock News, this sector view matters. The stock’s price rise came in a segment where its P/E is below the industry median, but its P/B is above it, while ROE and ROCE are stronger than the benchmark. That mix suggests investors should examine both valuation basis points and operating return quality rather than treating the move as a simple momentum trade.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,949.87	31.07	0.45	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,775.9	71.31	11.28	18.65	22.17
Hikal Ltd.	HIKAL	2,761.32	0	2.26	15.22	16.15
Sai Parenteral's Ltd.	SAIPARENT	2,594.65	179.52	3.32	13.9	12.97
Solara Active Pharma Sciences Ltd.	SOLARA	2,474.65	0	1.92	17.23	15.34

Syncom Formulations (India) Ltd. (SYNCOMF) has a P/E ratio of 17.88x compared with the displayed peer median of 31.07x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 18.04% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 20.72% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Syncom Formulations (India) Ltd. (SYNCOMF) has a market capitalisation of Rs 1,353.6 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Peer data shows Syncom Formulations (India) Ltd. sitting in the middle of a diverse listed pharmaceuticals group. Compared with supplied peers, the company is smaller in market capitalisation than several names in the sample, but its valuation and return profile look more balanced than some high-multiple or low-return counterparts.

At Rs 1,353.6 crore, Syncom Formulations is below Dishman Carbogen Amcis at Rs 2,949.87 crore, Beta Drugs at Rs 2,775.9 crore, Hikal at Rs 2,761.32 crore, Sai Parenteral's at Rs 2,594.65 crore and Solara Active Pharma Sciences at Rs 2,474.65 crore. It is also below Panacea Biotec, NGL Fine-Chem, Hester Biosciences, Ind-Swift Laboratories and Indoco Remedies on market capitalisation in this peer set.

On valuation, Syncom’s P/E of 17.88 is lower than Dishman Carbogen Amcis at 31.07, Beta Drugs at 71.31, Sai Parenteral's at 179.52, NGL Fine-Chem at 44.41, Ind-Swift Laboratories at 43.16 and Indoco Remedies at 355.2. It is, however, above Hester Biosciences at 15.51 among peers with a disclosed P/E. That positions the stock toward the lower end of the available peer P/E spectrum without being the cheapest in the set.

Its P/B of 3.29 is close to Sai Parenteral's at 3.32 and above Hikal at 2.26, Solara at 1.92, Panacea Biotec at 2.95, Ind-Swift Laboratories at 1.65, Indoco Remedies at 1.99 and especially Dishman Carbogen Amcis at 0.45. It remains well below Beta Drugs at 11.28 and NGL Fine-Chem at 6.49.

Profitability comparisons are also instructive. Syncom’s ROE of 18.04% is above Hikal’s 15.22%, Sai Parenteral's 13.9%, Solara’s 17.23%, Hester Biosciences’ 16.17%, Indoco Remedies’ 12.85%, Panacea Biotec’s 0% and Dishman Carbogen Amcis’ -2.89%, while it is slightly below Beta Drugs at 18.65% and well below NGL Fine-Chem at 27.9%. On ROCE, Syncom’s 20.72% exceeds Hikal’s 16.15%, Sai Parenteral's 12.97%, Solara’s 15.34%, Panacea’s 5.36%, Hester’s 14.12%, Ind-Swift’s 8.31% and Indoco’s 15.67%, while trailing Beta Drugs at 22.17% and NGL Fine-Chem at 33.91%.

For Univest readers, the takeaway is straightforward: Syncom Formulations (India) Ltd. Share Price is not being valued like the most expensive peer in the group, and its return ratios compare favourably with many of the supplied names. That helps explain why the stock can attract attention during a strong price day even without any verified catalyst in the data.

Why Investors Are Watching Syncom Formulations (India) Ltd.

Syncom Formulations (India) Ltd. Share Price is being watched because today’s move combines a double-digit gain with substantial volume and a set of fundamentals that compare reasonably well within the same pharmaceuticals industry. For Stock Market Today and Share Market Today screens, that makes it a relevant small-cap healthcare name.

• Verified price action: the stock rose 10.73% to Rs 16.1 from a previous close of Rs 14.54.
• Intraday range: it opened at Rs 15.5, moved between Rs 15.25 and Rs 17.16, and stayed above the previous close.
• Trading activity: total volume reached 4,30,08,703 shares, including 4,05,50,391 on NSE and 24,58,312 on BSE.
• Fundamental context: P/E is 17.88, P/B is 3.29, ROE is 18.04% and ROCE is 20.72%.
• Sector positioning: P/E is below the same-industry median of 24.45, while ROE and ROCE are above benchmark medians.

What investors may monitor next is whether Syncom Formulations (India) Ltd. Share Price continues to hold gains in relation to its intraday range and whether market attention keeps focusing on its valuation-versus-profitability mix. Univest sees this as a case where price action, earnings-linked valuation and industry benchmarking need to be read together, rather than in isolation.

About Syncom Formulations (India) Ltd.

Syncom Formulations (India) Ltd. is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied data, that places the company in a broad listed universe of 136 same-industry businesses used for benchmark comparison. For investors reading Syncom Formulations (India) Ltd. Stock News, that industry identity is important because pharmaceuticals stocks are often judged not only on price movement, but also on return ratios, valuation discipline and market-cap scale relative to peers.

The company’s market capitalisation of Rs 1,353.6 crore places it above the industry median market capitalisation of Rs 146.94 crore and the average of Rs 484.32 crore in the supplied benchmark set. That means Syncom is not operating at the smallest end of the Pharmaceuticals & Drugs listed space, even though it falls in the Small Cap category for market-screening purposes.

The metrics also place the company in a part of the sector where investors can compare operating returns and valuation with a meaningful peer basket. In the current data, companies such as Dishman Carbogen Amcis, Beta Drugs, Hikal, Sai Parenteral's, Solara Active Pharma Sciences, Panacea Biotec, NGL Fine-Chem, Hester Biosciences, Ind-Swift Laboratories and Indoco Remedies offer reference points on P/E, P/B, ROE, ROCE and market capitalisation. That is why Syncom Formulations (India) Ltd. Share Price Today is not just a market-movers item; it also sits within a clearly defined healthcare and pharmaceuticals comparison framework.

Track Syncom Formulations (India) Ltd. Share Price on Univest

Use Syncom Formulations (India) Ltd. (SYNCOMF) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors who want to follow Syncom Formulations (India) Ltd. Share Price more closely can track the stock on Univest for live share price moves, daily stock updates and market-cap changes. Univest also helps users monitor valuation ratios such as P/E and P/B, profitability indicators like ROE and ROCE, 52-week levels when available, and broader stock analysis across the NSE and BSE.

For readers looking up Syncom Formulations (India) Ltd. Share Price Today, Syncom Formulations (India) Ltd. Share Price Live or Syncom Formulations (India) Ltd. Latest News, the value lies in seeing price action alongside sector benchmarks and peer data rather than viewing one trading session in isolation. Univest keeps that framework central to how investors interpret market news, stock performance and company context.

Frequently Asked Questions

What is Syncom Formulations (India) Ltd. Share Price today?

Ans. Syncom Formulations (India) Ltd. Share Price was Rs 16.1 at the captured time on 12 August 2026. That reflected a same-day rise of 10.73% over the previous close of Rs 14.54, putting the stock among notable market movers.

Why is Syncom Formulations (India) Ltd. Share Price rising today?

Ans. The supplied data confirms that the stock rose 10.73% in the session, with strong participation of 4,30,08,703 total shares traded. It verifies the price event and trading activity, but does not establish any company-specific catalyst behind the move.

What were the day high, day low and opening price for Syncom Formulations shares?

Ans. The stock opened at Rs 15.5, touched an intraday high of Rs 17.16 and a low of Rs 15.25. Those levels show a wide trading range during the session, while the price remained above the previous close of Rs 14.54.

What is the market capitalisation of Syncom Formulations (India) Ltd.?

Ans. Syncom Formulations (India) Ltd. had a market capitalisation of Rs 1,353.6 crore in the supplied data. That places it in the Small Cap category, while still standing above the same-industry median market capitalisation of Rs 146.94 crore.

How much trading volume was recorded in Syncom Formulations today?

Ans. Total traded volume in Syncom Formulations shares was 4,30,08,703. Of this, BSE volume was 24,58,312 shares and NSE volume was 4,05,50,391 shares, indicating that today’s price rise came with broad market participation.

Is Syncom Formulations expensive based on P/E compared with its industry?

Ans. The company’s P/E ratio is 17.88, which is below the same-industry median of 24.45 and well below the average of 79.31. On the supplied numbers alone, its earnings multiple is lower than the broader benchmark midpoint.

How does Syncom Formulations compare on profitability?

Ans. Syncom Formulations reported ROE of 18.04% and ROCE of 20.72% in the supplied data. Both are above the industry medians of 10.49% and 12.97%, respectively, showing stronger profitability than the benchmark midpoint.

What are the key valuation ratios for Syncom Formulations?

Ans. The stock’s key valuation ratios in the data are P/E of 17.88 and P/B of 3.29. While the P/E sits below the industry median, the P/B is above the benchmark median of 1.82 and average of 2.46.

What does EPS and dividend yield show for Syncom Formulations?

Ans. EPS is Rs 0.81, which reflects the earnings attributable to each share and helps frame the stock’s 17.88 P/E ratio. Dividend yield is 0, so the current data reflects no historical cash yield relative to market price.

Which sector and industry does Syncom Formulations belong to?

Ans. Syncom Formulations belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark compares it with 136 same-industry companies, making sector and peer analysis especially useful for interpreting today’s share price rise.